![]() |
市場調查報告書
商品編碼
1889469
手術機器人市場預測至2032年:按產品、應用、控制機制、最終用戶和地區分類的全球分析Surgical Robot Market Forecasts to 2032 - Global Analysis By Offering (Robotic Systems, Instruments & Accessories, Software & Analytics, and Services), Application, Control Mechanism, End User, and By Geography |
||||||
根據 Stratistics MRC 的研究,預計到 2025 年,全球手術機器人市場價值將達到 95 億美元,到 2032 年將達到 298 億美元。
預計在預測期內,手術機器人市場將以17.7%的複合年成長率成長。手術機器人市場涵蓋機器人系統、器械和軟體,旨在輔助外科醫生進行微創手術。這些設備廣泛應用於泌尿系統、婦科、一般外科、整形外科和神經外科等專科。其優勢包括更高的手術精度、更佳的視野、在狹小空間內更便捷的操作、更小的切口帶來的出血量減少、更短的住院時間和更快的患者康復。同時,醫療機構也能從中受益,提高手術的一致性,並增強自身的競爭優勢。
根據 Intuitive Surgical 的文件和公開聲明,該公司預計在 2023 年安裝約 1370 台達文西手術系統,到 2023 年底,其安裝量將超過 8600 台,這表明其機器人手術平台將繼續擴張。
擴大微創手術的應用
手術機器人市場的主要驅動力之一是全球微創手術的加速發展。這些系統能夠透過較小的切口進行手術,從而顯著減輕患者的身體負擔,減少出血量,縮短住院時間,進而直接降低整體醫療成本並改善患者預後。隨著外科醫生和患者對這些優勢的認知不斷加深,泌尿系統和婦科等專科對機器人輔助手術技術的需求激增,迫使醫院投資這項技術以保持競爭力並滿足臨床需求。
極高的資本和營運成本
手術機器人帶來的沉重經濟負擔嚴重阻礙了其市場擴張。醫院購置初始系統需要數百萬美元的資本投入。此外,持續營運費用還包括昂貴的專用設備、強制性維護合約以及針對手術人員的大規模培訓項目。這一巨大的經濟障礙限制了手術機器人的普及,尤其是在對成本高度敏感的地區以及醫療預算有限的發展中地區。因此,高昂的總擁有成本仍是限制市場滲透的主要因素。
開發經濟高效的系統
目前,新參與企業和現有企業都致力於建立針對特定外科手術和中型醫院的價值工程系統。這項策略旨在普及機器人手術,並挖掘尚未開發的市場和門診手術中心的潛在需求。該領域的成功不僅能夠擴大基本客群,還可能加劇市場競爭,並刺激整個市場的進一步創新和價格調整。
監管障礙和核准延誤
目前,新參與企業和現有企業都致力於建造針對特定手術和中型醫院設計的價值工程系統。這項策略旨在普及機器人手術,並釋放尚未開發的市場和門診手術中心的潛在需求。該領域的成功不僅能夠擴大基本客群,還可能加劇市場競爭,並刺激整個市場的進一步創新和價格調整。
疫情初期,全球醫療系統為節約資源、控制感染風險而延後非緊急手術,導致醫療服務嚴重衝擊。這造成採用機器人輔助系統進行的擇期手術數量大幅下降。然而,這場危機也凸顯了自動化技術和微創手術在縮短住院時間和減少病患接觸方面的價值。隨著手術量的增加,對機器人手術平台的需求也隨之成長,從而提高了醫院的運作效率。這使得市場在疫情初期過後迅速復甦。
預計在預測期內,機器人系統細分市場將佔據最大的市場佔有率。
預計在預測期內,機器人系統領域將佔據最大的市場佔有率,因為每套新安裝的系統都需要銷售一套高價值的完整系統。技術的不斷進步,包括先進成像和數據分析技術的整合,正在推動系統的升級和新購買。此外,隨著新的醫院和手術中心進入機器人手術領域,它們的初始投資也集中於此核心硬體,從而鞏固了該領域在可預見的未來作為主要收入來源的地位。
預計在預測期內,整形外科和關節重建手術領域將達到最高的複合年成長率。
受全球骨關節炎患病率上升以及老齡化人口對膝關節和髖關節重建手術需求增加的推動,整形外科和關節置換手術領域預計將在預測期內實現最高成長率。機器人系統在骨骼準備和植入定位方面具有無與倫比的精準度,這對於改善關節功能和確保手術長期成功至關重要。機器人系統在實現穩定且可重複的手術結果方面已證實具有顯著的臨床優勢,這促使骨科醫生迅速採用這項技術,從而推動了其強勁的成長勢頭。
預計北美將在預測期內佔據最大的市場佔有率,這主要得益於其完善的醫療基礎設施、高昂的醫療支出以及對先進醫療技術的早期和廣泛應用。美國對機器人手術的支持性報銷政策以及主要市場參與者的強大影響力進一步鞏固了其主導地位。該地區完善的法規結構也促進了新系統的快速商業化,並確保先進臨床中心能夠持續獲得創新產品。
預計亞太地區在預測期內將實現最高的複合年成長率,這主要得益於中國、印度和日本等國醫療體系的快速發展、醫療旅遊業的成長以及醫院基礎設施現代化投資的增加。此外,龐大且老化的人口基數也對先進的外科手術服務產生了顯著需求。該地區的公立和私立醫院越來越重視機器人系統,將其視為提升服務水準和增強全球競爭力的策略性投資。
According to Stratistics MRC, the Global Surgical Robot Market is accounted for $9.5 billion in 2025 and is expected to reach $29.8 billion by 2032, growing at a CAGR of 17.7% during the forecast period. The surgical robot market covers robotic systems, instruments, and software that assist surgeons in performing minimally invasive procedures. It serves specialties such as urology, gynecology, general surgery, orthopedics, and neurosurgery. Benefits include enhanced precision, better visualization, improved dexterity in confined spaces, and smaller incisions that can reduce blood loss, shorten hospital stays, and support faster patient recovery, while hospitals gain from higher procedural consistency and competitiveness.
According to Intuitive Surgical company filings and public statements, Intuitive placed ~1,370 da Vinci surgical systems in 2023 and the installed base exceeded 8,600 systems by end-2023, illustrating continuing scale-up of robotic surgery platforms.
Growing Adoption of Minimally Invasive Surgery
The primary catalyst for the surgical robot market is the accelerating global shift towards minimally invasive procedures. These systems facilitate surgeries through small incisions, leading to significantly reduced patient trauma, less blood loss, and shorter hospital stays. This directly translates to lower overall healthcare costs and improved patient outcomes. As both surgeons and patients become more aware of these benefits, demand for robotic-assisted techniques in specialties like urology and gynecology is surging, compelling hospitals to invest in this technology to remain competitive and meet clinical demand.
Extremely High Capital and Operational Costs
The profound financial burden associated with surgical robots severely hinders market expansion. The initial purchase of a system represents a multi-million-dollar capital investment for hospitals. Furthermore, ongoing operational expenses include costly proprietary instruments, mandatory maintenance contracts, and extensive training programs for surgical staff. This significant financial barrier restricts adoption, especially in cost-sensitive settings and developing regions with constrained healthcare budgets. Consequently, the high total cost of ownership remains a major factor slowing broader market penetration.
Development of Cost-Effective Systems
New market entrants and established players are now focusing on creating value-engineered systems tailored for specific procedures or mid-tier hospitals. This strategy aims to democratize access to robotic surgery, unlocking latent demand in untapped markets and outpatient surgical centers. Success in this area would not only expand the customer base but also intensify competition, potentially driving further innovation and price adjustments across the entire market landscape.
Regulatory Hurdles and Approval Delays
New market entrants and established players are now focusing on creating value-engineered systems tailored for specific procedures or mid-tier hospitals. This strategy aims to democratize access to robotic surgery, unlocking latent demand in untapped markets and outpatient surgical centers. Success in this area would not only expand the customer base but also intensify competition, potentially driving further innovation and price adjustments across the entire market landscape.
The pandemic initially caused significant disruption, as healthcare systems worldwide deferred non-essential surgical procedures to conserve resources and manage infection risks. This led to a notable decline in elective surgeries performed with robotic systems. However, the crisis also underscored the value of automation and minimally invasive techniques in potentially reducing hospital stays and minimizing patient contact. As the number of surgeries increased, the demand for robotic platforms grew, and hospitals became more efficient. This helped the market recover quickly after the first phase.
The robotic systems segment is expected to be the largest during the forecast period
The robotic systems segment is expected to account for the largest market share during the forecast period because each new installation requires the sale of a complete, high-value system. The continuous technological evolution, including the integration of advanced imaging and data analytics, encourages upgrades and new purchases. Furthermore, as new hospitals and surgical centers enter the robotic surgery field, their initial investment is in this core hardware, securing this segment's position as the primary revenue generator for the foreseeable future.
The orthopedic & joint replacement surgery segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the orthopedic & joint replacement surgery segment is predicted to witness the highest growth rate, driven by a rising global prevalence of osteoarthritis and an aging population requiring procedures like knee and hip replacements. Robotic systems provide unparalleled precision in bone preparation and implant positioning, which is crucial for improving joint function and the longevity of these surgeries. The demonstrated clinical benefits in achieving consistent, reproducible outcomes are compelling orthopedic surgeons to rapidly adopt this technology, fueling its exceptional growth rate.
During the forecast period, the North America region is expected to hold the largest market share, anchored by a robust healthcare infrastructure, high healthcare expenditure, and early, widespread adoption of advanced medical technologies. Supportive reimbursement policies for robotic procedures in the U.S. and the strong presence of leading market players further consolidate its leading position. The region's well-established regulatory framework also facilitates quicker commercialization of new systems, ensuring a continuous pipeline of innovative products for its advanced clinical centers.
During the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by rapidly improving healthcare systems, growing medical tourism, and increasing investments in modernizing hospital infrastructure in countries like China, India, and Japan. Moreover, the large and aging population base is creating substantial demand for advanced surgical care. Governments and private hospitals in the region are increasingly viewing robotic systems as a strategic investment to enhance their service offerings and competitive stature on the global stage.
Key players in the market
Some of the key players in Surgical Robot Market include Intuitive Surgical, Inc., Stryker Corporation, Medtronic plc, Johnson & Johnson, Zimmer Biomet Holdings, Inc., Smith & Nephew plc, Siemens Healthineers AG, Renishaw plc, CMR Surgical Ltd, Globus Medical, Inc., Asensus Surgical, Inc., THINK Surgical, Inc., Vicarious Surgical Inc., and Medrobotics Corporation.
In October 2025, CMR announced plans to integrate AI via collaboration with NVIDIA to make surgical robotics smarter (leveraging data from every Versius procedure).
In October 2024, CMR Surgical received U.S. regulatory clearance (de novo) for its Versius system for gallbladder removal enabling U.S. use of its robotic surgery platform.
In August 2024, Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that it has signed a strategic development agreement with the LSU Health New Orleans.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.